OncoMatch

OncoMatch/Clinical Trials/NCT05414500

Mogamulizumab and Brentuximab Vedotin in CTCL and Mycosis Fungoides

Is NCT05414500 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including Mogamulizumab and Brentuximab vedotin for cutaneous t cell lymphoma.

Phase 1RecruitingUniversity of Alabama at BirminghamNCT05414500Data as of May 2026

Treatment: Mogamulizumab · Brentuximab vedotinThis is an open label, single center, non-randomized dose de-escalation phase I study of combination of BV and Mogamulizumab. The primary objective of the study is to assess the safety and tolerability of the combination. The primary objective is also to explore safe dose of combination for future expansion.

Check if I qualify

Extracted eligibility criteria

Cancer type

Non-Hodgkin Lymphoma

Biomarker criteria

Required: CD30 positivity (>1%)

Disease stage

Required: Stage II, III, IV

Performance status

ECOG 0–2(Ambulatory, capable of self-care)

Prior therapy

Min 1 prior line

Must have received: systemic therapy (bexarotene, interferons, extracorporeal photopheresis, methotrexate, gemcitabine, vorinostat)

Must have received at least one prior systemic therapy like bexarotene, interferons, ECP, methotrexate, Gemcitabine, Vorinostat etc. (patients who have received only skin directed therapy are not allowed)

Cannot have received: Brentuximab vedotin (Brentuximab vedotin)

Exception: Prior exposure of BV is allowed if it is >6 months ago and CD30+ in >1% of in biopsy after last BV

Prior exposure of BV < 6 months ago, or Moga. Prior exposure of BV is allowed if it is >6 months ago and CD30+ in >1% of in biopsy after last BV

Cannot have received: mogamulizumab (mogamulizumab)

Prior exposure of BV < 6 months ago, or Moga.

Lab requirements

Kidney function

estimated gfr >40 ml/min/1.73 m2

Liver function

t bili <2 x uln, isolated bilirubin of >2 is accepted if there is suspected diagnosis of gilbert's syndrome, ast and alt <3x uln

Cardiac function

lvef >40%

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

  • University of Alabama at Birmingham · Birmingham, Alabama

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify